We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. Markets closed

Tandem Diabetes Care, Inc. (TNDM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
25.89+0.44 (+1.73%)
At close: 4:00PM EDT
Full screen
Previous Close25.45
Open25.85
Bid25.74 x 1000
Ask25.85 x 1200
Day's Range24.59 - 26.20
52 Week Range2.14 - 26.24
Volume2,078,656
Avg. Volume2,495,173
Market Cap1.296B
Beta-0.69
PE Ratio (TTM)N/A
EPS (TTM)-8.74
Earnings DateJul 25, 2018 - Jul 30, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.36
Trade prices are not sourced from all markets
  • ACCESSWIRE3 days ago

    Free Stock Performance Review on TransEnterix and Three Additional Medical Supplies Stocks

    LONDON, UK / ACCESSWIRE / July 12, 2018 / If you want a free Stock Review on TRXC sign up now at www.wallstequities.com/registration. WallStEquities.com takes a close look at four Medical Instruments and Supplies stocks, particularly, Tandem Diabetes Care Inc. (NASDAQ: TNDM), The Cooper Cos. Inc. (NYSE: COO), TransEnterix Inc. (NYSE American: TRXC), and Waters Corp. (NYSE: WAT).

  • 2 Stocks That Turned $1,000 Into More Than $8,000 This Year
    Motley Fool6 days ago

    2 Stocks That Turned $1,000 Into More Than $8,000 This Year

    Just because risky stocks become winners doesn't mean you should be casting your lot with them.

  • The 5 Best Healthcare Stocks of 2018 (So Far)
    Motley Fool6 days ago

    The 5 Best Healthcare Stocks of 2018 (So Far)

    Here's what's pushing up the top-performing, non-pharmaceutical healthcare stocks.

  • Tandem Diabetes Care’s Stock Performance This Month
    Market Realist17 days ago

    Tandem Diabetes Care’s Stock Performance This Month

    On June 26, Tandem Diabetes Care (TNDM) ended the trading day at $23.64, ~7.3% lower than its 52-week low of $25.50 reached on June 22, triggered by news of the FDA’s approval of the company’s new insulin pump. On June 26, Tandem stock was trading ~1,000% higher than the 52-week low of $2.14 it reached on February 9.

  • What Tandem Diabetes Care Expects for This Year
    Market Realist17 days ago

    What Tandem Diabetes Care Expects for This Year

    In fiscal 2018, Tandem Diabetes Care (TNDM) expects sales at the mid-to-upper end of its $132 million–$140 million guidance. This confident sales outlook comes despite the company discontinuing its t:flex insulin pump by the end of fiscal Q2 2018. The company registered sales of $102.6 million in fiscal 2017 and $27.3 million in Q1 2018, ahead of analysts’ estimates.

  • Tandem Diabetes Care’s International Expansion Strategy
    Market Realist17 days ago

    Tandem Diabetes Care’s International Expansion Strategy

    Tandem Diabetes Care Rises 21%: Could It See More Upside? Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017. At the time, the move largely benefited Medtronic (MDT), the largest player in the insulin pump market.

  • Analysts’ Views on Tandem Diabetes Care after Its FDA Approval
    Market Realist17 days ago

    Analysts’ Views on Tandem Diabetes Care after Its FDA Approval

    After the market closed on June 21, Tandem Diabetes Care (TNDM) announced the FDA’s approval of its t:slim X2 insulin pump. Following the news, Oppenheimer analyst Steven Lichtman shared his views on Tandem, writing, “Approval timing is in line, though compatibility with Dexcom’s new G6 sensor in the initial approval is upside to expectations; TNDM had assumed a staggered approval with G5 compatibility first, potentially followed shortly thereafter by iCGM designation/G6 compatibility.” He added, “Earlier G6 approval bodes well for the initial launch later this summer. ...

  • Tandem’s Product Shipments Continue to Rise
    Market Realist18 days ago

    Tandem’s Product Shipments Continue to Rise

    Apart from selling insulin pumps, Tandem Diabetes Care (TNDM) also sells disposable products that are used together with pumps and are replaced every few days. These include cartridges and infusion sets. Tandem’s products on the market include t:slim, t:flex, and t:slim G4. In October 2016, Tandem commercialized t:slim X2 and discontinued t:slim. At present, the t:slim X2 platform represents almost the entire new pump shipments of the company. Tandem plans to discontinue sales of t:flex pumps from Q3 2018.

  • What to Expect from Tandem’s Product Pipeline
    Market Realist18 days ago

    What to Expect from Tandem’s Product Pipeline

    Tandem Diabetes Care’s (TNDM) t:slim X2 with control IQ is its second generation AID system that is expected to integrate the t:slim X2 pump with the technology Tandem licensed from TypeZero Technologies and Dexcom’s (DXCM) G6 sensor. In its international diabetes closed loop (or IDCL) trial, Tandem is working with TypeZero and Dexcom on the integration of their technologies. Further, Tandem plans to use these results in a premarket approval (or PMA) submission to the U.S. Food and Drug Administration (or FDA).

  • Analyzing Tandem’s Operational Performance
    Market Realist18 days ago

    Analyzing Tandem’s Operational Performance

    Due to the decrease in SG&A expenses, the total operating expenses of Tandem Diabetes Care decreased from $28.0 million in Q1 2017 to $26.9 million in Q1 2018, which further helped the company in reducing its operating loss to $15.5 million in Q1 2018 as compared with an operating loss of $21.2 million in Q1 2017.